Aventis sniffing out trouble
Executive Summary
Aventis is building a promotional campaign for Allegra around Schering-Plough's corporate-wide good manufacturing compliance difficulties. Aventis issued a press release March 14 declaring that it is "increasing production" of Allegra "to assure both patients and physicians that there will be an ample supply" for the spring allergy season. Aventis added that it is "taking steps to make increased supplies" of Nasacort AQ available, and that it is "prepared with substantial supplies of Azmacort." Schering-Plough says its supplies of Claritin are sufficient for the spring allergy season (1"The Pink Sheet" March 5, p. 6)
You may also be interested in...
Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems
Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials